Concerning the discordant results, we still need to conduct more large-scale clinical trials and in-depth basic experiments to further elucidate the essential role of ANGPTL4 in modulating the risk and the development of dyslipidemia in patients with hypothyroidism. Here, ANGPTL4 is linked to metabolic syndrome.